✦ Free PDF Download of Your Custom Analysis With Actionable Solutions After Token Purchase ✦
Token-based platform — single use from $1.99 · Pro packages available
SAMPLE ONLY
Prior Authorization — Ozempic (Semaglutide) · Aetna CVS Health · FL
PRISM® ANALYSIS REPORT · SAMPLE OUTPUT · March 2026
A prior authorization request for semaglutide (Ozempic) 0.5mg weekly subcutaneous injection was submitted to Aetna CVS Health for a 58-year-old patient with Type 2 Diabetes Mellitus (E11.9), Class II obesity (BMI 36.8), hypertension, and non-alcoholic fatty liver disease (NAFLD). The patient has documented failure of two sequential step-therapy agents — metformin (discontinued due to GI intolerance after 3 months) and glipizide (inadequate glycemic control after 6 months, A1C remaining at 9.1%).
The most likely denial risk for this submission is insufficient step-therapy documentation or a missing SGLT-2 inhibitor trial, depending on Aetna's current formulary tier requirements. This package addresses both risks directly and maps the clinical justification to each payer criterion.
SAMPLE LETTER — LETTER OF MEDICAL NECESSITY
[PRACTICE LETTERHEAD]
[DATE]
To: Aetna CVS Health Prior Authorization Department
Re: Prior Authorization Request — Ozempic (Semaglutide) 0.5mg Weekly
Patient: [REQUIRED: Patient full name]
Date of Birth: [REQUIRED]
Member ID: [REQUIRED: Aetna member ID]
Group Number: [REQUIRED]
Dear Prior Authorization Medical Director,
I am writing to request prior authorization for Ozempic (semaglutide) 0.5mg subcutaneous injection weekly for my patient, a 58-year-old individual with a primary diagnosis of Type 2 Diabetes Mellitus (ICD-10: E11.9). This request is medically necessary. The patient has documented failure of two step-therapy agents at adequate doses and durations, and presents with a high-risk metabolic profile for which a GLP-1 receptor agonist is the evidence-based, guideline-concordant next-line intervention.
STEP-THERAPY DOCUMENTATION
Agent 1: Metformin 1000mg daily
â–¸ Duration: 3 months
â–¸ Outcome: Discontinued due to clinically significant GI intolerance (nausea, diarrhea)
â–¸ Documentation: [REQUIRED: chart note specifying symptoms and clinical decision to discontinue]
Agent 2: Glipizide 10mg daily
â–¸ Duration: 6 months
▸ Outcome: Therapeutic failure — A1C remained at 9.1% at end of trial period
â–¸ Documentation: [REQUIRED: dated lab report showing A1C 9.1% during/after trial]
MEDICAL NECESSITY
The patient's current A1C of 9.1% with BMI 36.8, comorbid hypertension, and NAFLD represents a high-risk metabolic profile. GLP-1 receptor agonists are recommended by the American Diabetes Association (ADA) Standards of Care as preferred agents in patients with T2DM, obesity, and cardiovascular risk factors. Semaglutide addresses glycemic control, weight reduction, and cardiometabolic risk simultaneously — no adequately documented alternative achieves this in this patient's specific clinical context.
Denial of this request would leave a high-risk patient without guideline-concordant care following documented failure of available alternatives.
Sincerely,
[REQUIRED: Prescribing physician full name]
[REQUIRED: Credentials — MD, DO, etc.]
[REQUIRED: NPI number]
[REQUIRED: Practice name, address, phone, fax]
[REQUIRED: Signature]
RECOMMENDED DOCUMENTATION CHECKLIST
Completed and signed PA request form (Aetna provider portal or fax form)
→ Step-therapy section must list both agents: "Metformin 1000mg daily × 3 months — discontinued due to GI intolerance. Glipizide 10mg daily × 6 months — therapeutic failure; A1C 9.1% at end of trial."
REQUIRED
Chart note documenting metformin GI intolerance with specific symptoms
→ "Patient experienced [nausea / diarrhea / abdominal cramping] on metformin 1000mg daily. Metformin was discontinued after 3 months due to intolerable GI adverse effects."
REQUIRED
Chart note documenting glipizide therapeutic failure with lab evidence
→ "Patient trialed glipizide 10mg daily for 6 months. A1C remained at 9.1% — inadequate glycemic control. Therapy deemed a therapeutic failure."
REQUIRED
Dated HbA1c laboratory report (9.1%)
→ Must display: patient name, date of collection, result (9.1%), performing lab. Use the most recent result coinciding with the glipizide trial.
REQUIRED
Signed Letter of Medical Necessity
→ Signature block must include: "I certify that the above-described treatment is medically necessary based on documented therapeutic failure and the patient's high-risk metabolic profile."
REQUIRED
SGLT-2 inhibitor clinical rationale — address proactively if not trialed
→ [VERIFY WITH PAYER]: "SGLT-2 inhibitor therapy was not initiated because [specify clinical reason — eGFR contraindication, hypotension risk, or prescriber clinical judgment]."
RECOMMENDED
| Criterion | Documentation Provided | Status |
|---|
| FDA-approved indication (T2DM) | E11.9 confirmed; semaglutide FDA-approved for T2DM | ✓ MET |
| Diagnosis confirmed with objective data | HbA1c 9.1% documented | ✓ MET |
| Prescriber specialty appropriate | Dr. Johnson, Endocrinology | ✓ MET |
| Step therapy — metformin trialed | Metformin 1000mg × 3 months, GI intolerance documented | ⚠PARTIAL — requires chart note |
| Step therapy — sulfonylurea trialed | Glipizide 10mg × 6 months, therapeutic failure | ⚠PARTIAL — must appear on PA form |
| A1C threshold for advanced therapy | A1C 9.1% documented — exceeds typical threshold | ✓ MET |
| SGLT-2 inhibitor trial [VERIFY WITH PAYER] | Not documented in intake | ✗ GAP — confirm with Aetna policy |
| BMI / obesity documentation | BMI 36.8 documented | ✓ MET |
| Comorbidity documentation | Hypertension and NAFLD documented | ✓ MET |
| Signed Letter of Medical Necessity | LMN generated — requires physician signature | ⚠PARTIAL — requires signed LMN |
Florida Statutes §627.64741 — Step Therapy Override
Florida law gives patients the right to request a step therapy exception when they have already tried and failed required step agents, or when step therapy is clinically contraindicated. If Aetna's criteria require an SGLT-2 trial and the patient has a clinical reason to skip it, this statute supports the override request. Applies to fully insured commercial plans only — confirm ERISA status.
ADA Standards of Care in Diabetes (Current Annual Edition)
Recommends GLP-1 receptor agonist use in T2DM patients with obesity, cardiovascular risk, or NAFLD. Supports treatment escalation when HbA1c targets are not met on current regimen. Cite current edition year at time of submission.
ERISA Status Advisory
If this is a self-funded ERISA plan, Florida insurance statutes governing PA timelines and step therapy overrides may not apply. Confirm plan funding type from the insurance card or HR department before citing state-law rights in a formal appeal.
| Service Requested | Ozempic (semaglutide) 0.5mg subcutaneous injection, once weekly |
| Diagnosis (ICD-10) | E11.9 — Type 2 Diabetes Mellitus, without complications |
| Payer | Aetna CVS Health [VERIFY — confirm member ID card] |
| Plan Type | Commercial — ERISA status unknown |
| Prescribing Specialty | Endocrinology |
| Urgency | Routine |
| Submitting Provider NPI | [REQUIRED] |
| Patient Member ID | [REQUIRED] |
DECISION LOGIC IDENTIFIED
Aetna's GLP-1 prior authorization criteria for T2DM follow a multi-tier step therapy framework. The payer's automated criteria engine evaluates submitted documentation against each required tier sequentially. A missing tier — even if the clinical case is strong — triggers an automated denial.
The standard Aetna GLP-1 step therapy framework requires:
1. Tier 1: Metformin — documented trial with reason for discontinuation
2. Tier 2: Sulfonylurea OR DPP-4 inhibitor — documented trial with failure reason
3. Tier 3 (possible): SGLT-2 inhibitor — required by some Aetna formulary tiers before GLP-1 access
This submission documents Tier 1 (metformin, GI intolerance) and Tier 2 (glipizide, sulfonylurea, therapeutic failure). The critical variable is whether Aetna's current policy for this patient's formulary tier requires an SGLT-2 inhibitor trial before GLP-1 approval. This must be verified directly with Aetna prior to submission.
MISSING INFORMATION OR CRITERIA
The following gaps must be addressed before submission:
▸ SGLT-2 inhibitor trial — Not documented. Aetna's T2DM GLP-1 criteria may require an SGLT-2 agent as a step before GLP-1 approval, depending on formulary tier. Verify with Aetna's current Clinical Policy Bulletin for semaglutide before submitting. If required and not trialed, prepare a clinical exception argument citing eGFR, contraindication, or prescriber judgment.
▸ Glipizide not on structured PA form — The glipizide trial appears in the clinical narrative but must also be listed in the structured step-therapy field on the PA form. A discrepancy between the PA form and the LMN is a common denial trigger.
▸ Patient age inconsistency — Clinical summary references both age 56 and 58. Confirm and make consistent across all documents before submission. An age discrepancy is a flag that can delay review.
▸ Chart notes not yet attached — The metformin intolerance and glipizide failure notes are referenced but must be physically attached to the submission package.
MOST LIKELY SUCCESSFUL NEXT STEP
Verify Aetna's current SGLT-2 requirement for this formulary tier before submitting. Call Aetna Provider Services and ask: "Does your current clinical policy bulletin for semaglutide (Ozempic) for T2DM require an SGLT-2 inhibitor trial before GLP-1 approval for this patient's plan?" Document the rep's name and the date of the call.
If SGLT-2 is not required: submit the complete package as documented above with the two gaps addressed (glipizide on PA form, chart notes attached).
If SGLT-2 is required: add a physician attestation letter explaining the clinical reason the SGLT-2 step should be waived for this patient — citing A1C 9.1%, NAFLD, and BMI 36.8 as clinical grounds — and cite Florida's step therapy override statute.
OPTION 1 · If Initial PA Is Denied — File Level 1 Appeal
Request a formal Level 1 internal appeal within the deadline stated on the denial letter (typically 60–180 days). Include the complete documentation package above plus a physician attestation letter specifically addressing the denial reason. Appeal letters from specialty prescribers (endocrinologists) carry elevated evidentiary weight in Aetna PA appeals.
OPTION 2 · Peer-to-Peer Call
The prescribing endocrinologist can request a peer-to-peer (P2P) call with Aetna's medical director. P2P calls resolve GLP-1 denials at a significantly higher rate when comorbidities (hypertension, NAFLD, A1C > 9.0) are present and the prescriber can speak directly to the clinical rationale.
OPTION 3 · Manufacturer Patient Assistance
Novo Nordisk's NovoCare program offers income-based access to Ozempic while the authorization or appeal is pending. Application is patient-initiated and typically takes 3–5 business days. The prescriber's office can assist with the application.
Level 1 — Internal Appeal
File within the deadline stated on the denial letter. Request that the appeal be reviewed by a physician in the relevant specialty (endocrinology). Document all submission dates and tracking numbers.
Level 2 — External Independent Medical Review
If Level 1 is denied, file for an Independent Medical Review through the Florida Department of Insurance (for fully insured commercial plans). IMR decisions are legally binding on the insurer. GLP-1 denials with documented comorbidities overturn at a high rate at the IMR level.
Level 3 — Step Therapy Override (Florida)
Florida Statute §627.64741 provides a statutory right to request a step therapy exception. If Aetna's criteria require steps this patient has already failed or cannot safely attempt, cite this statute in the appeal. Applies to fully insured commercial plans — confirm ERISA status before invoking state law.
This case is navigable. The clinical profile is strong — A1C 9.1%, BMI 36.8, documented metformin intolerance, documented glipizide failure, NAFLD comorbidity. The denial risk is procedural, not clinical: the payer's criteria engine requires specific documentation in a specific format, and this package maps directly to each required criterion.
The single most important action before submission is verifying the SGLT-2 requirement. Everything else is documentation presentation. The prescribing endocrinologist has the clinical record to win this authorization — PRISM has mapped the path. Execute the checklist in order.
Call Aetna Provider Services and verify whether an SGLT-2 inhibitor trial is required for this patient's formulary tier — document rep name and call date
Add glipizide trial to the structured step-therapy section of the PA form (not just the LMN narrative)
Resolve patient age inconsistency (56 vs. 58) — confirm correct DOB across all documents
Attach chart note documenting metformin GI intolerance with specific symptom notation
Attach chart note documenting glipizide therapeutic failure with dated A1C lab report (9.1%)
Obtain physician signature on Letter of Medical Necessity before submission
If SGLT-2 is required: prepare clinical exception letter citing NAFLD, BMI 36.8, and Florida step therapy override statute
Submit complete package via Aetna provider portal — retain submission confirmation and tracking number
